U.S. flag

An official website of the United States government

Display Settings:

Format

Send to:

Choose Destination
Accession: PRJNA859660 ID: 859660

Bamlanivimab_targeted_S-gene_sequencing

Navigate Up
This project is a component of the INSDC SARS-CoV-2 Viral Sequencing Data
Navigate Across
961 additional projects are components of the INSDC SARS-CoV-2 Viral Sequencing Data.
As part of the ACTIV-2/A5401 randomized clinical trial (NCT04518410), non-hospitalized participants with symptomatic SARS-CoV-2 infection were given bamlanivimab (700mg or 7000mg) or placebo treatment. More...
AccessionPRJNA859660
Data TypeRaw sequence reads
ScopeMultispecies
Grants
  • "Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)" (Grant ID UM1 AI068634, National Institute of Allergy and Infectious Diseases Extramural Activities)
  • "AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections" (Grant ID UM1 AI068636, National Institute of Allergy and Infectious Diseases Extramural Activities)
  • "AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections" (Grant ID UM1 AI068636, National Institute of Allergy and Infectious Diseases Extramural Activities)
SubmissionRegistration date: 18-Jul-2022
Brigham & Women's Hospital
RelevanceMedical
Project Data:
Resource NameNumber
of Links
Sequence data
SRA Experiments271
Other datasets
BioSample271
SRA Data Details
ParameterValue
Data volume, Gbases4
Data volume, Mbytes1754

Supplemental Content

Related information

Recent activity

Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...
    You are here: NCBI
    Support Center